<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<GBSeq>

    <GBSeq_locus>PE185643</GBSeq_locus>
    <GBSeq_length>2211</GBSeq_length>
    <GBSeq_strandedness>double</GBSeq_strandedness>
    <GBSeq_moltype>DNA</GBSeq_moltype>
    <GBSeq_topology>linear</GBSeq_topology>
    <GBSeq_division>PAT</GBSeq_division>
    <GBSeq_update-date>04-AUG-2023</GBSeq_update-date>
    <GBSeq_create-date>04-AUG-2023</GBSeq_create-date>
    <GBSeq_definition>KR 1020220140537-A/21: GENE THERAPY FOR TREATING CDKL5 DEFICIENCY DISORDER</GBSeq_definition>
    <GBSeq_primary-accession>PE185643</GBSeq_primary-accession>
    <GBSeq_accession-version>PE185643.1</GBSeq_accession-version>
    <GBSeq_other-seqids>
      <GBSeqid>dbj|PE185643.1|</GBSeqid>
      <GBSeqid>pat|KR|1020220140537|21</GBSeqid>
      <GBSeqid>gi|2557762536</GBSeqid>
    </GBSeq_other-seqids>
    <GBSeq_keywords>
      <GBKeyword>KR 1020220140537-A/21</GBKeyword>
    </GBSeq_keywords>
    <GBSeq_source>Adeno-associated virus 9</GBSeq_source>
    <GBSeq_organism>Adeno-associated virus 9</GBSeq_organism>
    <GBSeq_taxonomy>Viruses; Monodnaviria; Shotokuvirae; Cossaviricota; Quintoviricetes; Piccovirales; Parvoviridae; Parvovirinae; Dependoparvovirus; Dependoparvovirus primate1</GBSeq_taxonomy>
    <GBSeq_references>
      <GBReference>
        <GBReference_reference>1</GBReference_reference>
        <GBReference_position>1..2211</GBReference_position>
        <GBReference_authors>
          <GBAuthor>Fyffe-Maricich,S.L.</GBAuthor>
          <GBAuthor>Fuller,M.S.</GBAuthor>
          <GBAuthor>Wright,M.C.</GBAuthor>
          <GBAuthor>Stoica,L.I.</GBAuthor>
          <GBAuthor>Craig,S.</GBAuthor>
          <GBAuthor>Daugherty,S.C.</GBAuthor>
        </GBReference_authors>
        <GBReference_title>GENE THERAPY FOR TREATING CDKL5 DEFICIENCY DISORDER</GBReference_title>
        <GBReference_journal>KR1020220140537-A 21 18-OCT-2022 ULTRAGENYX PHARMACEUTICAL INC</GBReference_journal>
      </GBReference>
    </GBSeq_references>
    <GBSeq_comment>KN KR 1020227029963-A/21~AN KR 1020227029963~AD 2022-08-30~PN KR 1020220140537~PD 2022-10-18~AT GENE THERAPY FOR TREATING CDKL5 DEFICIENCY DISORDER~AI Fyffe-Maricich, Sharyl Lynne|Fuller, Matthew Scott|Wright,~AI Margaret Caroline|Stoica, Lorelei Ioana|Craig,~AI Stewart|Daugherty, Sean Christopher~AA ULTRAGENYX PHARMACEUTICAL INC.~PR US 63/090,492=2020-10-12|US 62/976,483=2020-02-14~OS Adeno-associated virus 9~TY DNA~FH Key Location/Qualifiers.</GBSeq_comment>
    <GBSeq_feature-table>
      <GBFeature>
        <GBFeature_key>source</GBFeature_key>
        <GBFeature_location>1..2211</GBFeature_location>
        <GBFeature_intervals>
          <GBInterval>
            <GBInterval_from>1</GBInterval_from>
            <GBInterval_to>2211</GBInterval_to>
            <GBInterval_accession>PE185643.1</GBInterval_accession>
          </GBInterval>
        </GBFeature_intervals>
        <GBFeature_quals>
          <GBQualifier>
            <GBQualifier_name>organism</GBQualifier_name>
            <GBQualifier_value>Adeno-associated virus 9</GBQualifier_value>
          </GBQualifier>
          <GBQualifier>
            <GBQualifier_name>mol_type</GBQualifier_name>
            <GBQualifier_value>unassigned DNA</GBQualifier_value>
          </GBQualifier>
          <GBQualifier>
            <GBQualifier_name>db_xref</GBQualifier_name>
            <GBQualifier_value>taxon:235455</GBQualifier_value>
          </GBQualifier>
        </GBFeature_quals>
      </GBFeature>
    </GBSeq_feature-table>
    <GBSeq_sequence>atggctgccgatggttatcttccagattggctcgaggacaaccttagtgaaggaattcgcgagtggtgggctttgaaacctggagcccctcaacccaaggcaaatcaacaacatcaagacaacgctcgaggtcttgtgcttccgggttacaaataccttggacccggcaacggactcgacaagggggagccggtcaacgcagcagacgcggcggccctcgagcacgacaaggcctacgaccagcagctcaaggccggagacaacccgtacctcaagtacaaccacgccgacgccgagttccaggagcggctcaaagaagatacgtcttttgggggcaacctcgggcgagcagtcttccaggccaaaaagaggcttcttgaacctcttggtctggttgaggaagcggctaagacggctcctggaaagaagaggcctgtagagcagtctcctcaggaaccggactcctccgcgggtattggcaaatcgggtgcacagcccgctaaaaagagactcaatttcggtcagactggcgacacagagtcagtcccagaccctcaaccaatcggagaacctcccgcagccccctcaggtgtgggatctcttacaatggcttcaggtggtggcgcaccagtggcagacaataacgaaggtgccgatggagtgggtagttcctcgggaaattggcattgcgattcccaatggctgggggacagagtcatcaccaccagcacccgaacctgggccctgcccacctacaacaatcacctctacaagcaaatctccaacagcacatctggaggatcttcaaatgacaacgcctacttcggctacagcaccccctgggggtattttgacttcaacagattccactgccacttctcaccacgtgactggcagcgactcatcaacaacaactggggattccggcctaagcgactcaacttcaagctcttcaacattcaggtcaaagaggttacggacaacaatggagtcaagaccatcgccaataaccttaccagcacggtccaggtcttcacggactcagactatcagctcccgtacgtgctcgggtcggctcacgagggctgcctcccgccgttcccagcggacgttttcatgattcctcagtacgggtatctgacgcttaatgatggaagccaggccgtgggtcgttcgtccttttactgcctggaatatttcccgtcgcaaatgctaagaacgggtaacaacttccagttcagctacgagtttgagaacgtacctttccatagcagctacgctcacagccaaagcctggaccgactaatgaatccactcatcgaccaatacttgtactatctctcaaagactattaacggttctggacagaatcaacaaacgctaaaattcagtgtggccggacccagcaacatggctgtccagggaagaaactacatacctggacccagctaccgacaacaacgtgtctcaaccactgtgactcaaaacaacaacagcgaatttgcttggcctggagcttcttcttgggctctcaatggacgtaatagcttgatgaatcctggacctgctatggccagccacaaagaaggagaggaccgtttctttcctttgtctggatctttaatttttggcaaacaaggaactggaagagacaacgtggatgcggacaaagtcatgataaccaacgaagaagaaattaaaactactaacccggtagcaacggagtcctatggacaagtggccacaaaccaccagagtgcccaagcacaggcgcagaccggctgggttcaaaaccaaggaatacttccgggtatggtttggcaggacagagatgtgtacctgcaaggacccatttgggccaaaattcctcacacggacggcaactttcacccttctccgctgatgggagggtttggaatgaagcacccgcctcctcagatcctcatcaaaaacacacctgtacctgcggatcctccaacggccttcaacaaggacaagctgaactctttcatcacccagtattctactggccaagtcagcgtggagatcgagtgggagctgcagaaggaaaacagcaagcgctggaacccggagatccagtacacttccaactattacaagtctaataatgttgaatttgctgttaatactgaaggtgtatatagtgaaccccgccccattggcaccagatacctgactcgtaatctgtaa</GBSeq_sequence>
  </GBSeq>
